[EN] 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS 6,7-DIHYDROPYRAZOLO[1,5-A] PYRAZIN-4(5H)-ONE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DES RÉCEPTEURS MGLUR2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2016016395A1
公开(公告)日:2016-02-04
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
[EN] 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS DE 6,7-DIHYDROPYRAZOLO[1,5-Α]PYRAZIN-4(5H)-ONE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DES RÉCEPTEURS MGLUR2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2016087487A1
公开(公告)日:2016-06-09
The present invention relates to novel 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
Selective Single C(sp<sup>3</sup>)–F Bond Cleavage in Trifluoromethylarenes: Merging Visible-Light Catalysis with Lewis Acid Activation
作者:Kang Chen、Nele Berg、Ruth Gschwind、Burkhard König
DOI:10.1021/jacs.7b10755
日期:2017.12.27
motifs in the pharmaceutical chemistry, is highly atom- and step-economical. However, the singleC(sp3)-F bond cleavage of ArCF3 is a great challenge because of the chemical inertness of the C(sp3)-F bond and the difficult selectivity control of monodefluorination. We report here the first example of singleC(sp3)-F functionalization of trifluoromethylarenes via visible-light catalysis merged with
8-Substituted isoquinoline derivative and the use thereof
申请人:Kaneko Shunsuke
公开号:US20100261701A1
公开(公告)日:2010-10-14
The present invention relates to a compound represented by the following formula (1):
wherein D
1
, A
1
, D
2
, R
1
, D
3
, and R
2
each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
[EN] TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES ET INHIBITEURS DE JAK
申请人:NISSAN CHEMICAL IND LTD
公开号:WO2013024895A1
公开(公告)日:2013-02-21
Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a, L2a, L3a and na are as defined in the description.